Penumbra, Inc.

Healthcare · Medical - Devices

Overall research band Mixed

Quality Mixed

Valuation Very weak

Balance sheet Strong

Market confirmation Weak

One-minute company read

What this report can tell you now

What the company does

Penumbra, Inc. designs, develops, manufactures, and markets medical devices for use in the United States and internationally. Its main products include computer-assisted vacuum thrombectomy systems, peripheral thrombectomy products such as the Indigo System and Lightning Flash, arterial thrombectomy systems like Lightning Bolt 7, and access products including guide catheters and delivery catheters under brands such as Neuron and BENCHMARK. The company also offers integrated mechanical thrombectomy systems, neuro embolization coiling systems for treating aneurysms and neurovascular lesions, and peripheral embolization products like the Ruby Embolization Platform and Penumbra LANTERN Delivery Microcatheter. Additionally, Penumbra provides neurosurgical tools such as the Artemis Neuro Evacuation Device. Penumbra sells its products through direct sales organizations and distributors, generating revenue from the sale of these medical devices.

The current research profile is Mixed Setup, with valuation sensitive. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC12.0%Model input; read with the evidence status and period context.

Operating margin12.9%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years17.1%Model input; read with the evidence status and period context.

FCF margin14.6%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.